Glide Pharma Appoints Bryan G Morton as Chairman and Announces Board Changes
OXFORD, UK – 09 October 2013 – Glide Pharma, the pharmaceutical development and device company focused on the needle-free administration of solid dose formulations, today announced the appointment of Bryan G Morton as Non-Executive Chairman. The company also announced that Dr Charles Potter will step down from the Board and his role as Glide's Chief Business Officer.
Commenting on the announcement, Mark Kirby, Glide Pharma's outgoing Chairman, said, "Following the major progress Glide has made recently, I am pleased to hand over the Chairmanship to Bryan. His significant experience of building successful pharmaceutical companies will prove invaluable as Glide begins its next stage of development. I would also like to thank my fellow Board Directors for their help in guiding Glide to this point in its growth. In particular, I would like to thank Charles Potter, who originally developed Glide's SDI® technology and founded and led the company, and who has been instrumental in the company's success to date."
Commenting on his appointment, Bryan Morton, newly-appointed Chairman of Glide Pharma, said, "I have been impressed with Glide Pharma's recent progress, and welcome this opportunity to contribute to the company's future development. Having completed a significant investment round earlier this year and winning a large funding award from the UK Biomedical Catalyst, the company is well positioned, and I look forward to helping the team exploit the value of Glide's unique technology."
About Bryan Morton
Bryan Morton has over 30 years' experience as an entrepreneur and business leader in the life sciences industry. Most recently, he was Founder and Chief Executive of global oncology company EUSA Pharma, having raised $265 million from leading technology investors. The company was acquired by Jazz Pharmaceuticals in 2012 for $700 million. Prior to this, he founded and led Zeneus Pharma, a European specialty oncology and critical care company, which was subsequently acquired by Cephalon for $360 million. Previously, he was President of Convatec, EMEA (Bristol Myers Squibb), and prior to this he spent 20 years in positions of increasing seniority at Merck & Co. He currently is Chairman of Aircraft Medical, Energist, Oxford BioTherapeutics and ReNeuron and is a Non Executive Director on the Syncona LLP Board and Oxitec Board.
About Glide Pharma
Glide Pharma is a pharmaceutical development and device company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines. The company has a range of in-house and partnered programmes based on its proprietary solid dose injector, the Glide SDI®. Glide Pharma has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. The company has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT. For more information please visit www.glidepharma.com.